FdaApplication
BLA 125122
Identifiers
- fda_app_no: BLA125122
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 2006-02-03 |
Revenue by product
ROTATEQ
| Period | Revenue |
|---|---|
| Q2 2026 | $134.0M |
| Q1 2026 | $206.0M |
| Q4 2025 | $119.0M |
| Q3 2025 | $204.0M |
| Q2 2025 | $121.0M |
| Q1 2025 | $228.0M |
| Q4 2024 | $139.0M |
| Q3 2024 | $193.0M |
| Q2 2024 | $163.0M |
| Q1 2024 | $216.0M |
| Q4 2023 | $185.0M |
| Q3 2023 | $156.0M |
| Q2 2023 | $131.0M |
| Q1 2023 | $297.0M |
| Q4 2022 | $139.0M |
| Q3 2022 | $256.0M |
| Q2 2022 | $173.0M |
| Q1 2022 | $216.0M |
| Q4 2021 | $214.0M |
| Q3 2021 | $227.0M |
| Q2 2021 | $208.0M |
| Q1 2021 | $158.0M |
| Q4 2020 | $196.0M |
| Q3 2020 | $210.0M |
| Q2 2020 | $168.0M |
| Q1 2020 | $222.0M |
| Q4 2019 | $227.0M |
| Q3 2019 | $180.0M |
| Q2 2019 | $172.0M |
| Q1 2019 | $211.0M |
| Q4 2018 | $188.0M |
| Q3 2018 | $191.0M |
| Q2 2018 | $156.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ROTATEQ | — | 2.2X10E6 IU | Suspension |
| ROTATEQ | — | 2.2X10E6 IU | Suspension |
2 products